Insight Molecular Diagnostics Inc. — Director's Dealing 2020

May 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2020-05-07

Reporting Person: ANDREWS RONALD ASBURY (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-07	Restricted Stock Units	$	A	106221	Acquired		Common Stock (106221)	Direct

Footnotes

F1: Grant of restricted stock units under the OncoCyte 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock.

F2: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant.